文献速递神经免疫

六分钟步行试验作为儿童起病多发性硬化患者步行能力和耐力的测量指标

Six-Minute Walk as a Measure of Walking Capacity and Endurance in Patients With Pediatric-Onset Multiple Sclerosis.
PubMed 文献 · Neurology · 2022-11-07

本研究纳入45例儿童起病多发性硬化(POMS)患者和85名健康对照,评估其步行能力、耐力及日常活动行为。POMS患者6分钟步行距离显著短于对照(1848英尺 vs 2134英尺,p<0.0001),且无法在测试末加速至峰值速度;中高强度体力活动时间亦较少(20.4 vs 35.4 分钟/天,p=0.0003)。

要点

  • POMS患者6分钟步行距离较健康对照显著缩短(1848英尺 vs 2134英尺,p<0.0001)。
  • POMS患者6分钟步行末无法加速至峰值速度,提示步行耐力受限。
  • POMS患者中高强度体力活动时间少于对照(20.4 vs 35.4 分钟/天,p=0.0003)。

核心结论

  • POMS患者表现出更慢的6分钟步行表现和更少的中高强度日常体力活动,提示功能性步行能力、耐力和日常活动行为受限。
  • 步行耐力和能力受限在超重/肥胖且患多发性硬化的青少年中最为突出。

研究设计与样本

  • 招募18岁前诊断多发性硬化且年龄21岁或以下的青少年患者,并纳入健康对照。
  • 参与者完成问卷以量化疲劳、抑郁和体力活动水平,并完成计时2分钟和6分钟步行(6MW)测试以评估步行能力和耐力。
  • 参与者佩戴腰部加速度计以评估真实世界步行行为。
  • 共纳入45例POMS患者和85名对照参与者。

主要发现

  • POMS队列平均年龄16.9 ± 2.7岁,平均疾病病程2.8 ± 2.6年。
  • POMS队列中超重/肥胖比例高于对照(75% vs 33%)。
  • POMS患者6分钟步行距离显著短于对照(1848英尺 vs 2134英尺,p < 0.0001),且与对照不同,无法在6分钟步行末加速至峰值速度。
  • 体重指数类别和多发性硬化疾病显著影响6分钟步行表现。
  • 使用连续加速度测量,POMS患者中高强度体力活动时间少于对照(20.4 vs 35.4 分钟/天,p = 0.0003)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Despite low levels of disability, youth with pediatric-onset multiple sclerosis (POMS) engage in less physical activity compared with peers. The contribution of walking capacity, endurance, behavior, and MS comorbidities remains relatively undefined and may provide valuable insights into the limitations toward physical activity in youth with MS. The primary objective of this study was to investigate differences in walking capacity, endurance, and real-world behaviors of daily activity between youth with POMS and controls. METHODS: Youth diagnosed with MS prior to 18 years and aged 21 years or younger were recruited in addition to healthy controls. Participants completed questionnaires to quantify fatigue, depression, and physical activity levels and the timed 2- and 6-minute walk (6MW) as an assessment of walking capacity and endurance. Participants completed questionnaires to quantify fatigue, depression, and physical activity levels. Participants also completed the timed 2- and 6-minute walk (6MW) as an assessment of walking capacity and endurance and were sent home with a waist-worn accelerometer to assess real-world walking behavior. RESULTS: Forty-five patients with POMS and 85 control participants were enrolled. The POMS cohort had a mean age of 16.9 ± 2.7 years, with a mean disease duration of 2.8 ± 2.6 years. A greater proportion of the POMS cohort was overweight/obese compared with controls (75% vs 33%). Participants with MS walked a significantly shorter distance in 6 minutes compared with controls (1,848 feet vs 2,134 feet, p < 0.0001) and, unlike controls, were unable to accelerate to their peak speed at the end of the 6MW. Body mass index category and MS disease significantly affected 6MW performance. Using continuous accelerometry, participants with MS spent less time in moderate-to-vigorous physical activity compared with controls (20.4 vs 35.4 min/d, p = 0.0003). The POMS cohort reported significantly higher levels of depression and fatigue but self-reported similar levels of daily physical activity as controls. DISCUSSION: Youth with POMS exhibit slower 6MW performance and less daily engagement in moderate-to-vigorous physical activity, suggesting limitations in functional walking capacity, endurance, and daily activity behavior. Limitations in walking endurance and capacity are most prominent in those youth who are overweight/obese and living with MS. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that, compared with healthy controls, patients with POMS walk shorter distances on the 6MW test, are less able to accelerate to peak speed at the end of the test, and are less physically active.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Brenton JN, Florenzo B, Koshiya H, et al. Six-Minute Walk as a Measure of Walking Capacity and Endurance in Patients With Pediatric-Onset Multiple Sclerosis. Neurology. 2022. PMID: 35985830. doi:10.1212/WNL.0000000000201098

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。